The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.

Celltrion said on the 20th that it obtained additional approval from Health Canada for the auto-injector (AI) formulation of the autoimmune disease treatment biosimilar "Steqeyma" (ingredient name ...

Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

Risankizumab induces a rapid and sustained response in refractory Crohn disease (CD), according to study findings published ...

Drs Steven Feldman and Tina Bhutani-Jacques explore how next-generation oral therapies are closing the gap with biologics and ...

Johnson & Johnson stock is Tuesday's IBD Stock Of The Day. After years of sideways trade, J&J stock began a bullish streak ...

Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the first consensus definition of psoriasis on-treatment remission:Published by the National ...

Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford. Earlier today, Rani released financial ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ ...

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...

ECCO’26 focused on holistic care for inflammatory bowel disease, with multiple presentations focusing on ustekinumab ...